CN101007015A - Application of flavonoids of celery seed and coumarins in preparation of drug for preventing and treating gout - Google Patents

Application of flavonoids of celery seed and coumarins in preparation of drug for preventing and treating gout Download PDF

Info

Publication number
CN101007015A
CN101007015A CNA2007100628006A CN200710062800A CN101007015A CN 101007015 A CN101007015 A CN 101007015A CN A2007100628006 A CNA2007100628006 A CN A2007100628006A CN 200710062800 A CN200710062800 A CN 200710062800A CN 101007015 A CN101007015 A CN 101007015A
Authority
CN
China
Prior art keywords
soc
petroleum ether
celery seed
ethyl acetate
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2007100628006A
Other languages
Chinese (zh)
Other versions
CN100569241C (en
Inventor
陈海生
乔丽名
刘建国
李劲彤
高永良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING HUMANWELL JUNWEI PHARMACEUTICAL TECH CO LTD
Original Assignee
BEIJING TIANCHUAN JUNWEI MEDICINE TECHNOLOGY DEVELOPMENT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING TIANCHUAN JUNWEI MEDICINE TECHNOLOGY DEVELOPMENT Ltd filed Critical BEIJING TIANCHUAN JUNWEI MEDICINE TECHNOLOGY DEVELOPMENT Ltd
Priority to CNB2007100628006A priority Critical patent/CN100569241C/en
Publication of CN101007015A publication Critical patent/CN101007015A/en
Application granted granted Critical
Publication of CN100569241C publication Critical patent/CN100569241C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本发明公开了芹菜籽香豆素类和黄酮类化合物用于制备防治痛风药物、抗炎药物或保健食品中的用途，属于天然药物化学及医药技术领域。芹菜籽香豆素类和黄酮类化合物为芹菜籽乙酸乙酯萃取物，通过以下方法制备：芹菜干燥种子10kg，以15～20倍量75～95％(V/V)乙醇渗漉提取或以4～5倍量75～95％(V/V)乙醇加热提取3～4次，每次加热1～1.5小时；提取液减压浓缩至近无乙醇，得浓缩液；于浓缩液中加1～2倍量水稀释混悬后，用稀释液三分之一体积的石油醚(60～90℃)，萃取2～3次，分出石油醚并回收石油醚，得石油醚萃取物；水层再用三分之一体积乙酸乙酯萃取4次，分出乙酸乙酯并回收乙酸乙酯得芹菜籽乙酸乙酯萃取物。本发明制备工艺简单，得到的萃取物具有显著的抗炎疗效，并且能够降低大鼠血清尿酸量。

Figure 200710062800

The invention discloses the use of celery seed coumarins and flavonoids in the preparation of gout prevention and treatment drugs, anti-inflammatory drugs or health food, and belongs to the technical field of natural medicinal chemistry and medicine. Celery seed coumarins and flavonoids are celery seed ethyl acetate extracts, prepared by the following method: 10 kg of dried celery seeds are extracted by percolation with 15 to 20 times the amount of 75 to 95% (V/V) ethanol Or heat extraction with 4-5 times of 75-95% (V/V) ethanol for 3-4 times, heating for 1-1.5 hours each time; the extract is concentrated under reduced pressure until almost free of ethanol to obtain a concentrated solution; add After diluting the suspension with 1-2 times the amount of water, extract 2-3 times with petroleum ether (60-90°C) of one-third volume of the diluent, separate the petroleum ether and recover the petroleum ether to obtain petroleum ether extract; The aqueous layer was extracted four times with one-third volume of ethyl acetate, the ethyl acetate was separated and the ethyl acetate was recovered to obtain the celery seed ethyl acetate extract. The preparation process of the invention is simple, and the obtained extract has remarkable anti-inflammatory curative effect, and can reduce the amount of serum uric acid in rats.

Figure 200710062800

Description

Celery seed flavonoid and coumarin kind compound are prevented and treated the purposes of gout medicine in preparation
Technical field
The present invention relates to celery seed flavonoid and coumarin kind compound and prevent and treat the purposes of gout medicine in preparation, specifically, relate to the flavonoid of extraction separation from the seed of Herba Apii graveolentis Apium graveolens L. and coumarin kind compound and prevent and treat application in gout medicine, anti-inflammatory drug or the health food, belong to Natural Medicine Chemistry and medical technical field in preparation.
Background technology
Celery seed is the seed of samphire Herba Apii graveolentis Apium graveolens L., and the treatment arthralgia is existing century-old history in Australia, is regarded as traditional folk prescription among the people, takes the celery seed extracts and alleviate arthralgia.The cloudy step of modern nutriology is contained the nutritional labeling useful to articular cartilage in the seed oil of Herba Apii graveolentis certainly, is proved yet there is no strong evidence.The chemical constituent that the foreign scholar has reported is mainly umbelliferone, apiolin [Grag, S.K.; Gupta, S.R.; Sharma, N.D.Apiumoside, a new furanocoumarin glucoside from the seeds of Apiumgraveolens.Phytochemistry 1979b, 18,1764-1765], isoimpinellin, apiin, bergapton, Herba Apii graveolentis coumarin glycoside [Grag, S.K.; Gupta, S.R.; Sharma, N.D.Minor Phenolics of Apiumgraveolens seeds.Phytochemistry 1979a, 18,352.], Herba Apii graveolentis coumarin, seselin [Grag, S.K.; Gupta, S.R.; Sharma, N.D.Apiumetin-A New Furanocoumarin from the seeds of Apiumgraveolens.Phytochemistry 1978,17,2135-2136.].The pharmacologically active aspect, the existing report of xanthine oxidase inhibitory activity [Chun-Mao Lin about apigenin and luteolin, Chien-Shu Chen, Chien-Tsu Chen, Yu-Chih Liang.Molecular modeling of flavonoids that inhibits xanthine oxidase.Biochemical and Biophysical Research Communications, 2002,294:167-172], suppress the active report except that apigenin and luteolin have xanthine oxidase, other chemical compounds are not seen the report of preventing and treating gout and antiinflammatory action research both at home and abroad so far.
Summary of the invention
The technical problem to be solved in the present invention provides celery seed flavonoid and coumarin kind compound are prevented and treated the gout medicine in preparation purposes.
For achieving the above object, the present invention is by the following technical solutions:
Celery seed Coumarins and flavone compound are used for preparing the purposes of preventing and treating gout medicine, anti-inflammatory drug or health food, described celery seed Coumarins and flavone compound are the celery seed acetic acid ethyl ester extract, flavonoid content is 55-65% in the extract, and the content of Coumarins is 5-10%.
Described celery seed acetic acid ethyl ester extract prepares by the following method: Herba Apii graveolentis dry seed 10kg, with 15～20 times of amount 75～95% (V/V) ethanol percolate extraction or with 4～5 times of amount 75～95% (V/V) ethanol heating extraction 3～4 times, heated 1～1.5 hour at every turn; Extracting solution is evaporated to nearly no ethanol, gets concentrated solution; Add 1～2 times of water gaging dilution suspendible in concentrated solution after, the petroleum ether (60～90 ℃) with diluent 1/3rd volumes extracts 2～3 times, tells petroleum ether and reclaims petroleum ether, gets petroleum ether extract; Water layer reuse 1/3rd volume ethyl acetate extractions 4 times are told ethyl acetate and are reclaimed ethyl acetate and get the celery seed acetic acid ethyl ester extract.Obtain 12 flavone compounds and 6 Coumarins compounds from further separation of this extract and evaluation.
6 coumarin kind compounds are: SOC-1: umbelliferone [Chatterjee A., Sen R.and Ganguly D..Aegelinol, A minor Lactonic Constituent of Aegle Marmelos.Phytochemistry, 1978,17:328], SOC-2: xanthotoxol, [Elgamal M.H., N.H.Elewa, Elkhrisy E.A.. 13C NMRChemical shifts and carbon-proton coupling constants of some furocoumarins andfurochromones.Phytochemistry, 1979,18,139-143], SOC-3: bergapton [Elgamal M.H., Elewa N.H., Elkhrisy E.A..Helmut Duddeck.Phytochemistry, 1979,18:139-143], SOC-4:5,8-dimethoxy-6,7-furocoumarin [Chen.I.S., et al.Coumarins andanti-platelet aggregation constituents from Zanthoxylum schionifolium.Phytochemistry, 1995,39:1091], SOC-5:6-methoxyl group-umbelliferone [Melafferty F.W.and Douglas B.S..The wiley/NBS Registry of Mass Spectral Data.Volume1.], SOC-6: isoimpinellin [Tao Chaoyang, Chen Wansheng, Zhang Weidong. Zanthoxylum Dimorphophyllum Hemsl. Var Spinifolium Rhed. Et Wils Coumarins chemical constituent Acta Pharmaceutica Sinica, 2003, (28) 4,344-346].
12 flavone compounds are: SOC-7: chrysoeriol [Doo Y.C., Jeong Y.L., Kim M.R..Chrysoeriol potently inhibits the induction of nitric oxide synthase by blocking AP-1activation.Journal of Biomedical Science, 2005,12:949-959], SOC-8:5,7,3 ', 4 '-tetrahydroxy-3-methoxy flavone [Li Xiaodong, Wu Lijun, Zang Xiaoyan. northeast Cortex Sorbariae Arboreae The Chemical Constituents [J]. Chinese medicine is assorted, 2002,27 (11): 841-843.]; SOC-9: chrysoeriol 7-O-β-D-glucoside [Jia Zhongjian, Fei Houman, Li Yu; Zhu Ziqing. Saussurea medusa chemical analysis research (I). SCI; 1986,9 (7): 789-792], SOC-10 Quercetin [Xiang Guangya; Yang Yu; Ruan Jinlan. Radix Hyperici Monogyni (Herba Hyperici Monogyni) chemical constitution study [J]. Tongji Medical Univ's journal, 2001,30 (5): 481-483.] SOC-11: kaempferol [Zhang Chao, Fang Yanxiong. the separation and the evaluation of Chinese medicine Herba Melastomatis Dodecandri flavones ingredient. Chinese Pharmaceutical Journal, 2003,38 (4): 256-258], SOC-12: luteolin [Xie Mingyong, Yu Yingli, Wang Yuanxing etc. Cyclocarya paliurus Iljinskaja chromocor compound structure and content [J]. University Of Nanchang's journal (natural sciences version), 2003,27 (1): 49-52], SOC-13: apigenin [Cheng Yu bit of a bridle, Zhang Dongming, Yu Shishan, fourth is happy. wear the Rhizoma et radix smilacis santis The Chemical Constituents. and CHINA JOURNAL OF CHINESE MATERIA MEDICA, 2003,28 (3): 233-235], SOC-14: luteolin 3 '-O-β-D-glucoside [Mahmoud A.M., Nawwar S.H.andIrmgard M.Leaf phenolics of Punica granaturn.Phytochemistry, 1994,37 (4): 1175-1177], SOC-15: apigenin 7-O-β-D-glucoside [Bachir B., Albert J., Mourad K.and FrancoisT.Flavonoid glycosides from Erica Cinerea.Phytochemistry, 1992,31 (7): 2483-2486], SOC-16: luteolin 7-O-β-D-pyranglucoside [Zhang Chao, Fang Yanxiong, the separation and the evaluation of Chinese medicine Herba Melastomatis Dodecandri flavones ingredient. Chinese Pharmaceutical Journal, 2003,38 (4): 256-258], SOC-17:5,4 '-dihydroxy-6,7-methylene-dioxy isoflavone [Dhar KL, Kalla AK.A new isoflavone from Irisgermamca[J] .Phytochemistry, 1973,12 (4): 734-735], SOC-18: luteolin 7-O-[β-D-apiose (1 → 2)]-β-D-glucoside [Ochi T., Takaishi Y., Shibata H., Higuti T., Kataoka M.Chemical constituents of Capsicum annuum L var.angulosum, and antiHelicobacter pylori activity.Natural Medicines, 2005,59 (2): 76-84].
The present invention extracts, separates and has identified 6 coumarin kind compounds and 12 flavone compounds from celery seed Apium graveolens L..Coumarin kind compound in the discovery celery seed and flavone compound can be used for preparation and prevent and treat gout medicine, anti-inflammatory drug or health food medicine.
Chrysoeriol is used for preparing the purposes of preventing and treating gout medicine, anti-inflammatory drug or health food.
The compositions that contains chrysoeriol is used for preparing the purposes of preventing and treating gout medicine, anti-inflammatory drug or health food.
The chemical constitution of 6 coumarin compounds is as follows:
Figure A20071006280000061
Figure A20071006280000062
SOC-1 umbelliferone (Umbelliferone) SOC-2 xanthotoxol (Xanthotoxin)
Figure A20071006280000063
Figure A20071006280000064
SOC-3 bergapton SOC-4 5,8-dimethoxy-6,7-furocoumarin
(Bergapten) (5，8-Dimethoxy-furo[6，7]-2H-1-benzopyran-2-one)
Figure A20071006280000071
Figure A20071006280000072
SOC-5 6-methoxyl group-umbelliferone SOC-6 isoimpinellin
(Scopolean) (Isopimpinellin)
The chemical constitution of 12 flavone compounds is as follows:
Figure A20071006280000074
SOC-7 chrysoeriol SOC-8 5,7,3 ', 4 '-tetrahydroxy-3-methoxy flavone
(Chrysoeriol) (5，7，3’，4’-tetrahydroxy-3-methoxy flavonol)
SOC-9 chrysoeriol 7-O-β-D-glucoside SOC-10 Quercetin (Quercetin)
(Chrysoeriol-7-O-β-D-glucoside)
Figure A20071006280000076
SOC-11 kaempferol (Kaempferol) SOC-12 luteolin (Luteolin)
Figure A20071006280000081
SOC-13 apigenin (Apigenin) SOC-14 luteolin 3 '-O-β-D-glucoside
(Luteolin 3’-O-β-D-glucoside)
Figure A20071006280000082
SOC-15 apigenin-7-O-B-D-glucoside SOC-16 luteolin 7-O-β-D-pyranglucoside
Apigenin 7-O-β-D-glucoside) (luteolin 7-O-β-D-glucoside)
Figure A20071006280000083
SOC-17 5,4 '-dihydroxy-6,7-methylene-dioxy isoflavone
(5，4’-dihydroxy-6，7-methylenedioxy isoflavone)
Figure A20071006280000091
SOC-18 luteolin 7-O-[β-D-apiose (1 → 2)]-β-D-glucoside
{luteolin 7-O-[2-(β-D-apiofuranosyl)-β-D-glucopyranoside]}
We adopt the rat gout model due to the micro-crystal type uric acid sodium, Oteracil Potassium induced mice hyperuricemia model, the uricopoiesis method is measured the activity test of xanthine oxidase vitro inhibition, the superoxide ion method of formation is measured xanthine oxidase vitro inhibition activity test and the test of pyrogallol autoxidation, found that chromocor compound and coumarin compound in the celery seed (Apium graveolens L.) have the formation of the uric acid of inhibition, promote urate excretion and antiinflammatory action.Therefore, chromocor compound in the celery seed and coumarin compound can be used to prepare the purposes of preventing and treating gout medicine or food or anti-inflammatory drug.
Advantage of the present invention is: the celery seed acetic acid ethyl ester extract that the present invention has found chrysoeriol first and contained this chemical compound has the effect of significant inhibition uricopoiesis, is the competitive inhibitor of xanthine oxidase.Coumarins and flavone compound can also reduce rat blood serum uric acid amount in the celery seed of the present invention, can be used for preparation and prevent and treat gout medicine, anti-inflammatory drug or health food.
The invention will be further described below in conjunction with the drawings and specific embodiments; it is not limitation of the invention; according to prior art well known in the art; embodiments of the present invention are not limited to this; therefore all this areas of having done according to the disclosure of invention be equal to replacement, all belong to protection scope of the present invention.
Description of drawings
Fig. 1 for be substrate with the xanthine of low concentration to the XO of chrysoeriol suppress active Lineweaver-burk mapping (0 μ M ,-; 0.5 μ M, *; 2.5 μ M, △; 5 μ M,; 10 μ M, zero).
The specific embodiment
Embodiment 1 celery seed flavonoid and coumarin compound preparation method
Herba Apii graveolentis dry seed 10kg with 95% (V/V) ethanol percolate extraction, collects 15 times of amount percolates, and extracting solution is evaporated to nearly no ethanol in 55 ℃, thick extractum.After extractum added 1 times of water gaging dilution suspendible, the petroleum ether (60～90 ℃) with diluent 1/3rd volumes extracted 3 times, told petroleum ether and reclaimed the petroleum ether extract of petroleum ether.Water layer reuse 1/3rd volume ethyl acetate extractions 4 times are told ethyl acetate and are reclaimed ethyl acetate and get the celery seed acetic acid ethyl ester extract, and this extract mainly contains the celery seed coumarin and the flavone compound component is represented with (CFE).Flavonoid content is 55-65% in the extract, and the content of Coumarins is 5-10%.
Embodiment 2 celery seed flavonoids and coumarin compound preparation method
Herba Apii graveolentis dry seed 10kg with 75% (V/V) ethanol percolate extraction, collects 20 times of amount percolates, and extracting solution is evaporated to nearly no ethanol in 55 ℃, thick extractum.After extractum added 2 times of water gagings dilution suspendibles, the petroleum ether (60～90 ℃) with diluent 1/3rd volumes extracted 2 times, told petroleum ether and reclaimed the petroleum ether extract of petroleum ether.Water layer reuse 1/3rd volume ethyl acetate extractions 4 times are told ethyl acetate and are reclaimed ethyl acetate and get the celery seed acetic acid ethyl ester extract, and this extract mainly contains the celery seed coumarin and the flavone compound component is represented with (CFE).Flavonoid content is 55-65% in the extract, and the content of Coumarins is 5-10%.
Embodiment 3 celery seed flavonoids and coumarin compound preparation method
Herba Apii graveolentis dry seed 10kg with 4 times of amount 95% (V/V) ethanol heating extraction 3 times, heated 1 hour at every turn; Collect extracting solution, be evaporated to nearly no ethanol in 55 ℃, thick extractum.After extractum added 1 times of water gaging dilution suspendible, the petroleum ether (60～90 ℃) with diluent 1/3rd volumes extracted 3 times, told petroleum ether and reclaimed the petroleum ether extract of petroleum ether.Water layer reuse 1/3rd volume ethyl acetate extractions 4 times are told ethyl acetate and are reclaimed ethyl acetate and get the celery seed acetic acid ethyl ester extract, and this extract mainly contains the celery seed coumarin and the flavone compound component is represented with (CFE).Flavonoid content is 55-65% in the extract, and the content of Coumarins is 5-10%.
Embodiment 4 celery seed flavonoids and coumarin compound preparation method
Herba Apii graveolentis dry seed 10kg with 5 times of amount 75% (V/V) ethanol heating extraction 4 times, heated 1.5 hours at every turn; Collect extracting solution, be evaporated to nearly no ethanol in 55 ℃, thick extractum.After extractum added 2 times of water gagings dilution suspendibles, the petroleum ether (60～90 ℃) with diluent 1/3rd volumes extracted 3 times, told petroleum ether and reclaimed the petroleum ether extract of petroleum ether.Water layer reuse 1/3rd volume ethyl acetate extractions 4 times are told ethyl acetate and are reclaimed ethyl acetate and get the celery seed acetic acid ethyl ester extract, and this extract mainly contains the celery seed coumarin and the flavone compound component is represented with (CFE).Flavonoid content is 55-65% in the extract, and the content of Coumarins is 5-10%.
Embodiment 5 silica gel column chromatographies prepare celery seed coumarin and flavone compound monomer
Celery seed acetic acid ethyl ester extract (CFE) 80g (pressing the preparation of embodiment 1 method), silica gel (200～300 orders, the yellow affair silica gel of Yantai sesame development experiments factory product) column chromatography is separated (φ 10 * 120cm, 1000g), and petroleum ether-ethyl acetate (50: 1,25: 1,9: 1,8: 2,1: 1) gradient elution, every 1000ml collects, be divided into part for 1-30, pillar reuse eluent ethyl acetate behind the gradient elution, every 500ml collects, and being divided into is 10 parts.Behind the decompression and solvent recovery, in the 5th, 7 and 11 part, can obtain compound S OC-2, the crystallization of SOC-3 and SOC-4.The 14th part once more silica gel column chromatography separate that (φ 4 * 40cm 100g), can obtain compound S OC-6, SOC-1 and SOC-5 behind petroleum ether-ethyl acetate (20: 1,15: 1,10: the 1) gradient elution.The the 17th, 18 and 20 part obtains compound S OC-7, SOC-13 and SOC-17.The 22nd, 24,26 and 27 parts obtain chemical compound and obtain compound S OC-8, SOC-11, SOC-10 and SOC-12.The 30th part obtains chemical compound and obtains compound S OC-9.The eluent ethyl acetate part, after 1,2 and 3 part of merging, (φ 2.5 * 40cm 100g), behind methanol-water (8: the 2) eluting, obtains compound S OC-14 and SOC-15 to the separation of C18 reversed-phase silica gel column chromatography once more.The eluent ethyl acetate part, after the 5th, the 6 and 7 part of merging, C once more 18((φ 2.5 * 40cm 100g), behind methanol-water (8: the 2) eluting, obtains compound S OC-16 and SOC-18 to reverse phase silica gel in the column chromatography separation.Above chemical compound is through mass spectrograph (Mat-212 magnetic-type) and nuclear magnetic resonance analyser (Bruker DRX-500 type) is measured and contrast the chemical constitution of having determined them with document.
Embodiment 6 uricopoiesis methods are measured xanthine oxidase vitro inhibition activity
1. material and method
(1) reagent
Xanthine (xanthine) is available from U.S. Sigma company; Allopurinol (allopurinol) is available from U.S. Sigma company; Xanthine oxidase (xanthine oxidase) is available from Roche company; Pyrophosphoric acid sodium salt (sodiumpyrophosphate decahydrate ace reagent) is available from ICN Biomedical company;
Chrysoeriol, apigenin and luteolin make by embodiment 5 separation and purification.
(2) measure uricopoiesis
Add 50 μ g/ml samples or positive control allopurinol (1 μ g/ml) in the 1mmol xanthine solution, add 0.1U/ml xanthine oxidase (XO), add sodium pyrophosphate buffer solution (80mmol/1, pH value 8.5) in the reaction system to final volume 1ml, reaction is beginning to add xanthine oxidase, 37 ℃ of reaction 5min, automatic clinical chemistry analyzer (Hitachi-7600-020) measures the uricopoiesis amount, with the uricopoiesis amount of 5min as response speed.
2. experimental result
By calculating the xanthine oxidase inhibitory activity power that the uricopoiesis suppression ratio detects given the test agent.Chrysoeriol (SOC-7), apigenin (SOC-13) and luteolin (SOC-12) are external to have remarkable inhibiting activity to xanthine oxidase (XO).
Further detect chrysoeriol (SOC-7), these three monomers of apigenin (SOC-13) and luteolin (SOC-12) when variable concentrations to the vitro inhibition activity of xanthine oxidase, its experimental result shows that its inhibitory action is dose-dependence, with inhibitor concentration to suppression ratio map three's 50 3nhibitory dose (IC 50), suppress activity intensity: chrysoeriol (IC 505.6 allopurinol (IC μ M), 506.8 apigenin (IC μ M), 509.5 luteolin (IC μ M), 5010.5 μ M).(above numerical value is the meansigma methods that detects three times, has passed through statistical procedures: SAS statistics software).
By changing concentration of substrate, detect enzymatic reaction speed, to chrysoeriol Lineweaver-Burk mapping (Fig. 1), to detect its enzyme suppressor mode, the result shows that chrysoeriol has significantly suppressed the generation of uric acid, is the competitive inhibitor of xanthine oxidase.
Embodiment 7 superoxide ion method of formation are measured XO and are suppressed active and the experiment of pyrogallol autoxidation
1. material and method
(1) medicine and reagent
Xanthine (xanthine); Allopurinol (allopurinol); Tetrazolium nitro nitroblue (Nitro BlueBtetrazolium); Superoxide dismutase (superoxide dismutase) is available from U.S. Sigma company; Xanthine oxidase (xanthine oxidase represents with XO) is available from Roche company; Pyrogallol is available from Shanghai Chemical Reagent Co., Ltd., Sinopharm Group;
(2) utilize superoxide ion to cause NBT chromogenic assay xanthine oxidase activity
Reaction system is divided into three groups, wherein model group only adds xanthine (50 μ mol/l), xanthine oxidase (0.1U/mol) and NBT (50 μ mol/l), and on the basis of model group, add the chrysoeriol (SOC-7) of 20,40 and 60 μ g/ml in the experimental group respectively again by the concentration of sample chrysoeriol (SOC-7), positive controls adds the allopurinol of 1 μ g/ml on the model group basis, add phosphate buffer (50mmol/l, pH value 7.2) in the reaction system to final volume 600 μ l.Reaction is beginning to add xanthine oxidase, room temperature reaction 5min, under 560nm, measure optical density with the CE-2021 spectrophotometer, wavelength 560nm,, compared after the optical density value that experimental group and positive controls are recorded is calculated its suppression ratio divided by the optical density value of model group as response speed with the optical density recruitment of per minute.Xanthine is dissolved in 1 μ mol/l NaOH, other components dissolved are in 50mmol/l phosphate buffer and solution that 0.1mmol/LEDTA joins [Valentao P., Fernandes E., Carvalho F., et al.Antioxidant activity ofcentaurium erythraea infusion evidenced by its superoxide badical scavenging and xanthineoxidase inhibitory activity[J] .J.Agric.Food Chem., 2001,49:3476-3479].
(3) pyrogallol autoxidation test
It is model group, chrysoeriol (SOC-7) sample sets (being further divided into 20,40 and 60 μ g/ml concentration groups by its concentration) that experiment is divided into three groups, and positive control SOD (100u/ml) group.Before adding pyrogallol, add the material in sample sets and the positive controls earlier, behind 25 ℃ of constant temperature 20min, add the pyrogallol of 25 ℃ of preheatings, shake up rapidly, in the impouring optical path 1cm cuvette, measure light absorption value A at wavelength 420nm place immediately O, A The chrysoeriol sampleAnd A SODSuppression ratio=(A O-A The chrysoeriol sample/ A SOD) A O* 100% [40]
(4) influence of the foundation of hyperuricemia model and chrysoeriol
Male Kunming strain mice, body constitution amount 18～22g, be divided into 6 groups at random, every group 10, be sham operated rats, model group, high, medium and low dosage chrysoeriol (SOC-7) group and allopurinol group, high, medium and low dosage intraperitoneal injection every day is 1 time in the experiment, and continuous 3d, the dosage of high, medium and low dosage group chrysoeriol (SOC-7) are respectively 10,20,30mgkg -1, allopurinol dosage is 2mgkg -1Administration in the end one day, model group gives the equal volume normal saline, 1h before the last 1d administration, all organize equal lumbar injection 900mgkg except that sham operated rats -1Oteracil Potassium, the 1h posterior orbit is got blood, with automatic clinical chemistry analyzer measure uric acid level in the serum [Wang Haidong, Ge Fei. the Herba Antenoronis Neofiliformis (Herba Antenoronis Filiformis) extract is to the influence [J] of hyperuricemia mice. CHINA JOURNAL OF CHINESE MATERIA MEDICA, 2002,22 (12): 939-9].
(5) statistical procedures
SAS statistics software, the result all x ± s represent.The t check of data is in groups adopted in experiment in the body.
2. experimental result
(1) chrysoeriol (SOC-7) is to the influence of xanthine oxidase activity
Cause NBT determination of color superoxide ion growing amount by superoxide ion, show that chrysoeriol (SOC-7) has significant inhibitory effect to xanthine oxidase, calculates its half-inhibition concentration (IC 50) be 3.2 μ M.
(2) chrysoeriol (SOC-7) is to the influence (table 1) of hyperuricemia mice serum uric acid level
Model group mice serum uric acid level has been compared obvious rising with sham operated rats, the high, medium and low dosage group of chrysoeriol is compared with model group, and remarkable decline is all arranged, and illustrates that chrysoeriol (SOC-7) also has the uric acid resisting effect in vivo.
Table 1 chrysoeriol is to the result that influences with uric acid level in the uricase inhibition Oteracil Potassium processing mice serum
Group Mice (only) Dosage (mgkg -1) Serum uric acid level (μ molml -1)
Model group 10 - 0.305±0.089
Sham operated rats 10 - 0.075±0.200#
Chrysoeriol (SOC-7) 10 10 0.260±0.076 *
Chrysoeriol (SOC-7) 10 20 0.235±0.066 **
Chrysoeriol (SOC-7) 10 30 0.216±0.048 **
The allopurinol group 10 2 0.139±0.037 **
Chrysoeriol and model group are relatively *P＜0.05, *P＜0.01; Model group and sham operated rats compare: #P＜0.05.
The anti-inflammatory activity research of embodiment 8 celery seed flavonoids and coumarin kind compound
1. material and method
(1) medicine and reagent:
Celery seed acetic acid ethyl ester extract (CFE) (flavonoid and Coumarins) is pressed the preparation of embodiment 1 method.
The aspirin enteric coatel tablets: Qinyang, Henan pharmaceutical factory produces, lot number: 20030314, and specification: 0.3g/ sheet.
Uric acid: Shanghai Foxing Changzheng medical science Co., Ltd, lot number: G041003.
Uric acid calibration solution: Shanghai Foxing Changzheng medical science Co., Ltd, lot number: G031191.
Experiment test instrument: rat foot claw tester: the semi-automatic enzymatic analysis instrument of Crony-800 type.
The preparation of crystallite uric acid sodium (MSU): get 8 gram uric acid and place 1600ml boiling water, transfer PH to 7.4, reheat to 95 degree, the room temperature cooling is also stirred gently, filters, and gets crystallite uric acid sodium, 200 ℃ of sterilizations are in the preceding suspension that is made into 100mg/ml with anhydrous normal saline.
(2) laboratory animal and grouping and dosage
Influence to rat paw edema: SD Sprague Dawley rat, 30, male and female half and half, 180～230 grams.Be divided into 3 groups at random, 10 every group, be respectively the normal saline matched group, aspirin matched group (0.25g/kg), CFE treatment group (1g/kg).
The rat urate excretion is influenced: 30 of SD rats, be divided into 3 groups at random, 10 every group, be respectively the normal saline matched group, aspirin matched group (0.25g/kg), CFE organizes (1g/kg).
(3) celery seed acetic acid ethyl ester extract (CFE) is measured the influence of pedal swelling
Under the sterile working, the MSU suspension 0.1ml that has prepared is injected in the subcutaneous inflammation that causes of the right back toes of rat, cause scorching preceding 30 minutes and give gastric infusion earlier, volume is 10ml/kg, and pedal swelling rate (basic value E (%)=(Vt-Vn)/vn * 100Vn and Vt represent respectively and cause the average swelling degree that the scorching sufficient sole of the foot volumetric values in front and back and inhibitory rate of intumesce I (%)=(Ec-Et)/Ec * 100 Et and Ec are represented administration group and matched group respectively) is measured in administration after 24 hours.
(4) celery seed acetic acid ethyl ester extract (CFE) is measured the influence of urate excretion
Under the sterile working, with the MSU suspension 0.1ml subcutaneous injection that has prepared, every day 2 times, continuous 10 days, 2 hours eye sockets were got blood and are surveyed serum uric acid concentration after the administration in the 11st day 1 time.
2. experimental result
Cause the gout outbreak by the sodian deposition of micro-crystal type uric acid in joint tissue and set up rat model, observe influence and the uricotelism of celery seed acetic acid ethyl ester extract (CFE) pedal swelling due to the uric acid.
(1) to the influence of rat paw edema rate and suppression ratio
A. rat paw edema rate:
Matched group causes scorching back 24 hours and causes scorching back 1 hour and compare at the sufficient sole of the foot, and the swelling degree does not have and alleviates; Compared the swelling degree in back 1 hour and obviously alleviate and CFE administration group causes scorching back 24 hours swelling degree and cause inflammation.See Table 2
Influence (%) N=10 of table 2 pair rat paw edema rate
Time after the administration (hour)
Group normal saline group aspirin group CFE group 1 11.6±5.68 21.0±8.17 15.2±5.98 3 15.9±4.93 18.5±9.53 20.2±7.55 5 24.7±8.57 16.5±0.41 21.7±6.74 7 18.1±5.69 12.6±7.78 18.0±7.67 24 12.9±7.65 9.68±5.67 10.6±6.83
B. to the influence of 24 hours suppression ratio of rat paw edema:
Credit is analysed by statistics, and positive control drug aspirin inhibitory rate of intumesce is 24.9%; The CFE inhibitory rate of intumesce is 10.1%, sees Table 3.
Influence (%) n=10 of table 3 pair rat paw edema 24h suppression ratio
Group Suppression ratio
Aspirin group CFE group 24.9 20.1
(2) to the influence of rat blood serum uric acid level
Through gastric infusion continuous 10 days of every day 2 times, uric acid in the serum is measured in eyeball blood sampling back, compares with the normal saline matched group, and CFE group serum uric acid level significantly reduces (P＜0.05), sees Table 4.
The influence of table 4 pair rat blood serum uric acid
Group Uric acid level (umol/l)
Normal saline group aspirin group CFE group 294.7±84.0 198.996±8.8 * 209.68±63.3 *
*Compare with matched group P＜0.05.
Conclusion:
The result of the test of above embodiment 6-8 shows: by micro-crystal type uric acid sodium rat model, celery seed flavonoid and coumarin kind compound to the influence of pedal swelling due to the uric acid with and diuretic activity, can alleviate the pedal swelling that causes by MSU and play antiphlogistic effect, and can reduce rat blood serum uric acid amount.And generate two kinds of methods and detected xanthine oxidase vitro inhibition activity by measuring uricopoiesis and superoxide ion.Proved that further chrysoeriol (SOC-7) has certain uric acid resisting effect to the Oteracil Potassium mouse model.From present research data, Coumarins in the celery seed and flavone compound have possessed preparation and have prevented and treated gout medicine, anti-inflammatory drug or health food primary condition.Therefore, Coumarins and flavone compound can be used for preparation and prevent and treat gout medicine, anti-inflammatory drug or health food in the celery seed of the present invention.

Claims (9)

1. celery seed Coumarins and flavone compound are used for preparing the purposes of preventing and treating gout medicine, anti-inflammatory drug or health food.
2. purposes according to claim 1 is characterized in that: described celery seed Coumarins and flavone compound are the celery seed acetic acid ethyl ester extract.
3. purposes according to claim 2, it is characterized in that: described celery seed acetic acid ethyl ester extract prepares by the following method: Herba Apii graveolentis dry seed 10kg, with 15～20 times of amount 75～95% (V/V) ethanol percolate extraction or with 4～5 times of amount 75～95% (V/V) ethanol heating extraction 3～4 times, heated 1～1.5 hour at every turn; Extracting solution is evaporated to nearly no ethanol in 55 ℃, concentrated solution; Add 1～2 times of water gaging dilution suspendible in concentrated solution after, the petroleum ether (60～90 ℃) with diluent 1/3rd volumes extracts 2～3 times, tells petroleum ether and reclaims petroleum ether, gets petroleum ether extract; Water layer reuse 1/3rd volume ethyl acetate extractions 4 times are told ethyl acetate and are reclaimed ethyl acetate and get the celery seed acetic acid ethyl ester extract.
4. according to claim 1 or 2 or 3 described purposes, it is characterized in that: described celery seed acetic acid ethyl ester extract contains following monomer: SOC-1: umbelliferone, SOC-2: xanthotoxol, SOC-3: bergapton, SOC-4:5,8-dimethoxy-6, the 7-furocoumarin, SOC-5:6-methoxyl group-umbelliferone, SOC-6: isoimpinellin and 10 flavone compound: SOC-7: chrysoeriol, SOC-8:5,7,3 ', 4 '-tetrahydroxy-3-methoxy flavone, SOC-9: chrysoeriol 7-O-β-D-glucoside, the SOC-10 Quercetin, SOC-11: kaempferol, the SOC-12 luteolin, the SOC-13 apigenin, SOC-14: luteolin 3 '-O-β-D-glucoside, SOC-15: apigenin 7-O-β-D-glucoside, SOC-16: luteolin 7-O-β-D-pyranglucoside, SOC-17:5,4 '-dihydroxy-6,7-methylene-dioxy isoflavone and SOC-18: luteolin 7-O-[β-D-apiose (1 → 2)]-β-D-glucoside.
5. chrysoeriol is used for preparing the purposes of preventing and treating gout medicine, anti-inflammatory drug or health food.
6. the compositions that contains chrysoeriol is used for preparing the purposes of preventing and treating gout medicine, anti-inflammatory drug or health food.
7. celery seed acetic acid ethyl ester extract, it is characterized in that preparing as follows: Herba Apii graveolentis dry seed 10kg, with 15～20 times of amount 75～95% (V/V) ethanol percolate extraction or with 4～5 times of amount 75～95% (V/V) ethanol heating extraction 3～4 times, heated 1～1.5 hour at every turn; Extracting solution is evaporated to nearly no ethanol in 55 ℃, concentrated solution; Add 1～2 times of water gaging dilution suspendible in concentrated solution after, the petroleum ether (60～90 ℃) with diluent 1/3rd volumes extracts 2～3 times, tells petroleum ether and reclaims petroleum ether, gets petroleum ether extract; Water layer reuse 1/3rd volume ethyl acetate extractions 4 times are told ethyl acetate and are reclaimed ethyl acetate and get the celery seed acetic acid ethyl ester extract.
8. celery seed acetic acid ethyl ester extract according to claim 7, it is characterized in that: described extract contains following chemical compound: SOC-1: umbelliferone, SOC-2: xanthotoxol, SOC-3: bergapton, SOC-4:5,8-dimethoxy-6, the 7-furocoumarin, SOC-5:6-methoxyl group-umbelliferone, SOC-6: isoimpinellin and 10 flavone compound: SOC-7: chrysoeriol, SOC-8:5,7,3 ', 4 '-tetrahydroxy-3-methoxy flavone, SOC-9: chrysoeriol 7-O-β-D-glucoside, the SOC-10 Quercetin, SOC-11: kaempferol, the SOC-12 luteolin, the SOC-13 apigenin, SOC-14: luteolin 3 '-O-β-D-glucoside, SOC-15: apigenin 7-O-β-D-glucoside, SOC-16: luteolin 7-O-β-D-pyranglucoside, SOC-17:5,4 '-dihydroxy-6,7-methylene-dioxy isoflavone and SOC-18: luteolin 7-O-[β-D-apiose (1 → 2)]-β-D-glucoside.
9. the preparation method of celery seed acetic acid ethyl ester extract, it is characterized in that: Herba Apii graveolentis dry seed 10kg, with 15～20 times of amount 7～95% (V/V) ethanol percolate extraction or with 4～5 times of amount 75～95% (V/V) ethanol heating extraction 3～4 times, heated 1～1.5 hour at every turn; Extracting solution is evaporated to nearly no ethanol in 55 ℃, concentrated solution; Add 1～2 times of water gaging dilution suspendible in concentrated solution after, the petroleum ether (60～90 ℃) with diluent 1/3rd volumes extracts 2～3 times, tells petroleum ether and reclaims petroleum ether, gets petroleum ether extract; Water layer reuse 1/3rd volume ethyl acetate extractions 4 times are told ethyl acetate and are reclaimed ethyl acetate and get the celery seed acetic acid ethyl ester extract.
CNB2007100628006A 2007-01-17 2007-01-17 Celery Seed Ethyl Acetate Extract and Its Uses Expired - Fee Related CN100569241C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2007100628006A CN100569241C (en) 2007-01-17 2007-01-17 Celery Seed Ethyl Acetate Extract and Its Uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2007100628006A CN100569241C (en) 2007-01-17 2007-01-17 Celery Seed Ethyl Acetate Extract and Its Uses

Publications (2)

Publication Number Publication Date
CN101007015A true CN101007015A (en) 2007-08-01
CN100569241C CN100569241C (en) 2009-12-16

Family

ID=38695825

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2007100628006A Expired - Fee Related CN100569241C (en) 2007-01-17 2007-01-17 Celery Seed Ethyl Acetate Extract and Its Uses

Country Status (1)

Country Link
CN (1) CN100569241C (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102048775A (en) * 2010-12-09 2011-05-11 北京人福军威医药技术开发有限公司 Celery seed extract composition and preparation method thereof
CN101274936B (en) * 2007-03-27 2011-06-15 大闽食品（漳州）有限公司 Preparation for furocoumarin compound 4 - hydroxy-9-(3,7-dimethylocata-1,6-dien-3-yl)-7H-furo[3,2-g] chromen-7-one and application of the compound
CN102106516A (en) * 2011-01-25 2011-06-29 天津科技大学 Use of vegetable extract in inhibiting xanthine oxidase (XO) and application in preparing food for preventing and treating hyperuricemia or gout
CN102224910A (en) * 2011-05-17 2011-10-26 江南大学 A method for producing food ingredients rich in nitrite and flavonoids by utilizing celery leaves
CN102603835A (en) * 2012-02-13 2012-07-25 国家海洋局第二海洋研究所 Method for extracting celery flavone with stepwise enzymolysis method
EP2303302A4 (en) * 2008-04-28 2013-02-27 Kent Truscott PREPARATION AND METHOD FOR RELIEVING OR PREVENTING THE SYMPTOMS ASSOCIATED WITH URICIC ACID CRYSTALS
CN103183654A (en) * 2013-01-30 2013-07-03 泰山医学院 Separation purification preparation process for activated monomers of celery seeds
CN104012729A (en) * 2014-06-11 2014-09-03 杨平 Tea substitute bag capable of lowering uric acid
CN104490910A (en) * 2014-12-03 2015-04-08 南京睿鹰润泽生物医药科技有限公司 Composition containing active components of dracocephalum moldavica l. and used for resisting myocardial ischemia-reperfusion injury
CN105535048A (en) * 2016-01-04 2016-05-04 中国科学院昆明植物研究所 Application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout
CN105560262A (en) * 2016-01-04 2016-05-11 中国科学院昆明植物研究所 Application of Graveobioside A in preparation of drugs or healthcare food for preventing hyperuricemia and gout
CN106474169A (en) * 2016-03-25 2017-03-08 珠海赛隆药业股份有限公司 A kind of Celeryseed extract and its preparation and preparation method
CN106883278A (en) * 2017-03-21 2017-06-23 广东药科大学 A kind of 3,5,7 trihydroxy 2 (4 hydroxy phenyl) ketone derivatives of chromene 4
CN107158205A (en) * 2017-06-14 2017-09-15 安徽大学 A kind of pharmaceutical composition for treating hypertension
WO2017193985A1 (en) 2016-05-12 2017-11-16 北京人福军威医药技术开发有限公司 Compound celery seed and sophora flower bud extract and medical use thereof
CN109045138A (en) * 2018-09-26 2018-12-21 渤海大学 A kind of compound celery seed tablet and preparation method thereof assisting in the treatment of gout
CN109400750A (en) * 2018-12-05 2019-03-01 吉林浩泰健康产业发展有限公司 A kind of preparation method of avenabeta glucosan
CN110585252A (en) * 2019-08-27 2019-12-20 杨凌萃健生物工程技术有限公司 Celery seed extract and preparation method thereof
CN111617071A (en) * 2019-02-27 2020-09-04 苏州凯祥生物科技有限公司 Hyperuricemia pharmaceutical composition and drug for treating hyperuricemia
CN111808154A (en) * 2020-08-06 2020-10-23 天津中医药大学 Purification method and application of dihydroparenol-β-D-glucoside
CN112716989A (en) * 2020-10-26 2021-04-30 山东大学 Celery seed extract and preparation method and application thereof
CN115120604A (en) * 2021-03-24 2022-09-30 陕西凤丹正元生物科技有限公司 Application of apigenin 7-O-glucoside as preparation for reducing uric acid and gouty arthritis
CN116715648A (en) * 2023-06-20 2023-09-08 江苏邦平科技有限公司 A class of compounds based on the flavonoid apigenin linked to citric acid
CN117064926A (en) * 2022-08-03 2023-11-17 山东大学 Application research of component analysis and functions of flavonoid extract of seeds of Umbelliferae plants
JP2024534971A (en) * 2021-09-10 2024-09-26 キョンブク ナショナル ユニヴァーシティ インダストリー－アカデミック コオペレーション ファウンデーション Composition for preventing, improving or treating diseases associated with muscle weakness, comprising celery seed extract as an active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ267567A (en) * 1993-06-25 1997-10-24 Main Camp Marketing Pty Ltd Su Treatment of inflammatory conditions using various indole, benzoquinone and benzofuran derivatives; method of plant material extraction; celery seed extract
JP4231559B2 (en) * 1997-04-23 2009-03-04 オリザ油化株式会社 Lipoxygenase inhibitor
WO2002085394A1 (en) * 2001-04-24 2002-10-31 Bakulesh Mafatlal Khamar The process of preparing the topical anti-inflammatory/analgesic preparation

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101274936B (en) * 2007-03-27 2011-06-15 大闽食品（漳州）有限公司 Preparation for furocoumarin compound 4 - hydroxy-9-(3,7-dimethylocata-1,6-dien-3-yl)-7H-furo[3,2-g] chromen-7-one and application of the compound
EP2303302A4 (en) * 2008-04-28 2013-02-27 Kent Truscott PREPARATION AND METHOD FOR RELIEVING OR PREVENTING THE SYMPTOMS ASSOCIATED WITH URICIC ACID CRYSTALS
CN102048775A (en) * 2010-12-09 2011-05-11 北京人福军威医药技术开发有限公司 Celery seed extract composition and preparation method thereof
CN102048775B (en) * 2010-12-09 2012-11-07 北京人福军威医药技术开发有限公司 Celery seed extract composition and preparation method thereof
CN102106516A (en) * 2011-01-25 2011-06-29 天津科技大学 Use of vegetable extract in inhibiting xanthine oxidase (XO) and application in preparing food for preventing and treating hyperuricemia or gout
CN102106516B (en) * 2011-01-25 2012-12-12 天津科技大学 Use of vegetable extract in inhibiting xanthine oxidase (XO) and application in preparing food for preventing and treating hyperuricemia or gout
CN102224910A (en) * 2011-05-17 2011-10-26 江南大学 A method for producing food ingredients rich in nitrite and flavonoids by utilizing celery leaves
CN102224910B (en) * 2011-05-17 2013-01-02 江南大学 Method for producing food ingredient rich in nitrite and flavonoid by use of celery leaves
CN102603835A (en) * 2012-02-13 2012-07-25 国家海洋局第二海洋研究所 Method for extracting celery flavone with stepwise enzymolysis method
CN103183654A (en) * 2013-01-30 2013-07-03 泰山医学院 Separation purification preparation process for activated monomers of celery seeds
CN103183654B (en) * 2013-01-30 2014-11-05 泰山医学院 Separation purification preparation process for activated monomers of celery seeds
CN104012729A (en) * 2014-06-11 2014-09-03 杨平 Tea substitute bag capable of lowering uric acid
CN104490910B (en) * 2014-12-03 2017-05-31 南京睿鹰润泽生物医药科技有限公司 A kind of Dracocephalum moldavica active ingredient compositions of the reperfusion injury that resists myocardial ischemia
CN104490910A (en) * 2014-12-03 2015-04-08 南京睿鹰润泽生物医药科技有限公司 Composition containing active components of dracocephalum moldavica l. and used for resisting myocardial ischemia-reperfusion injury
CN105535048A (en) * 2016-01-04 2016-05-04 中国科学院昆明植物研究所 Application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout
CN105560262A (en) * 2016-01-04 2016-05-11 中国科学院昆明植物研究所 Application of Graveobioside A in preparation of drugs or healthcare food for preventing hyperuricemia and gout
CN106474169A (en) * 2016-03-25 2017-03-08 珠海赛隆药业股份有限公司 A kind of Celeryseed extract and its preparation and preparation method
CN106474169B (en) * 2016-03-25 2022-04-12 珠海赛隆药业股份有限公司 Celery seed extract, preparation and preparation method thereof
WO2017193985A1 (en) 2016-05-12 2017-11-16 北京人福军威医药技术开发有限公司 Compound celery seed and sophora flower bud extract and medical use thereof
CN106883278A (en) * 2017-03-21 2017-06-23 广东药科大学 A kind of 3,5,7 trihydroxy 2 (4 hydroxy phenyl) ketone derivatives of chromene 4
CN107158205B (en) * 2017-06-14 2020-06-23 安徽大学 A pharmaceutical composition for treating hypertension
CN107158205A (en) * 2017-06-14 2017-09-15 安徽大学 A kind of pharmaceutical composition for treating hypertension
CN109045138A (en) * 2018-09-26 2018-12-21 渤海大学 A kind of compound celery seed tablet and preparation method thereof assisting in the treatment of gout
CN109400750A (en) * 2018-12-05 2019-03-01 吉林浩泰健康产业发展有限公司 A kind of preparation method of avenabeta glucosan
CN111617071A (en) * 2019-02-27 2020-09-04 苏州凯祥生物科技有限公司 Hyperuricemia pharmaceutical composition and drug for treating hyperuricemia
CN111617071B (en) * 2019-02-27 2023-05-23 苏州凯祥生物科技有限公司 Hyperuricemia medicine composition and medicine for treating hyperuricemia
CN110585252A (en) * 2019-08-27 2019-12-20 杨凌萃健生物工程技术有限公司 Celery seed extract and preparation method thereof
CN111808154A (en) * 2020-08-06 2020-10-23 天津中医药大学 Purification method and application of dihydroparenol-β-D-glucoside
CN112716989A (en) * 2020-10-26 2021-04-30 山东大学 Celery seed extract and preparation method and application thereof
CN115120604A (en) * 2021-03-24 2022-09-30 陕西凤丹正元生物科技有限公司 Application of apigenin 7-O-glucoside as preparation for reducing uric acid and gouty arthritis
JP2024534971A (en) * 2021-09-10 2024-09-26 キョンブク ナショナル ユニヴァーシティ インダストリー－アカデミック コオペレーション ファウンデーション Composition for preventing, improving or treating diseases associated with muscle weakness, comprising celery seed extract as an active ingredient
CN117064926A (en) * 2022-08-03 2023-11-17 山东大学 Application research of component analysis and functions of flavonoid extract of seeds of Umbelliferae plants
CN117064926B (en) * 2022-08-03 2025-06-06 山东大学 Application research of component analysis and functions of flavonoid extract of seeds of Umbelliferae plants
CN116715648A (en) * 2023-06-20 2023-09-08 江苏邦平科技有限公司 A class of compounds based on the flavonoid apigenin linked to citric acid

Also Published As

Publication number Publication date
CN100569241C (en) 2009-12-16

Similar Documents

Publication Publication Date Title
CN101007015A (en) Application of flavonoids of celery seed and coumarins in preparation of drug for preventing and treating gout
TWI454269B (en) Compounds isolated from xanthoceras sorbifolia, methods for preparing same and uses thereof
CN102018766A (en) Plant extractive, extraction method and application thereof as well as composite comprising same
CN101863871B (en) Total glycosides of Rhodiola rosea, medical application and preparation method thereof
Lin et al. Screening of xanthine oxidase inhibitor from selected edible plants and hypouricemic effect of Rhizoma Alpiniae Officinarum extract on hyperuricemic rats
Yu et al. Hypoglycemic activity of Origanum vulgare L. and its main chemical constituents identified with HPLC-ESI-QTOF-MS
CN101940616A (en) Preparation method of effective part of Clinopodium chinense (Benth.) O. Kuntze for preventing and treating diabetes and medicine application thereof
CN102302560A (en) Composition of lucid ganoderma extract and tartary buckwheat extract, as well as application thereof
CN103919857A (en) Folium eucalypti extractive with uric acid reduction effect as well as preparation method and application thereof
Qi et al. Toxicological studies of wogonin in experimental animals
CN103860638B (en) Preparation method of sophora alopecuroide flavonoid composition and new medical application
CN104306427A (en) Rhodiola rosea extract and application thereof
Tang et al. The potential of Chinese medicines in the treatment of hyperuricemia
CN103816213A (en) Method for extracting medication composition from amorpha fruticosa root and novel medical application
CN104224863B (en) Lysimachia herb total flavone is preparing the application in treating antihyperuricemic disease drug
CN105079085A (en) Extraction process of total flavonoids of oxytropis falcata
CN109078134A (en) It is a kind of that not only there is Chinese medicine composition and preparation method thereof that is anti-oxidant but also can reduce gout patients serum Uric Acid Concentration
CN102875615B (en) Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf
CN105963342A (en) An antiallergic compound flavone composition, and a preparing method and applications thereof
Sunarni et al. Constituent and antihyperuricemic activity of Stelechocarpus burahol leaves subfractions
CN104147104B (en) Subprostrate sophora flavone composition is being prepared with the application in reducing blood glucose while anti-curing hyperlipemia medicine
CN105030914B (en) Application of the Ligustrum robust Folum Ilicis extract in alpha-glucosidase restrainer
CN104162058A (en) Traditional Chinese medicine compound preparation for treating gout and preparation method thereof
CN103405494A (en) Bauhinia championii n-butyl alcohol extract and preparation method and application thereof
CN103044377B (en) Compounds and composition with effects of inhibiting xanthine oxidase and reducing uric acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: YICHANG HUMANWELL PHARMACEUTICAL CO., LTD.

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: BEIJING HUMANWELL JUNWEI PHARMACEUTICAL TECH CO.,

Free format text: FORMER NAME: BEIJING TIANCHUN JUNWEI MEDICINE TECHNOLOGY DEVELOPMENT CO., LTD.

CP03 Change of name, title or address

Address after: 102600, Beijing Daxing District bio pharmaceutical industry base, No. 11, wing Rong Street, Sinopharm

Patentee after: Beijing Humanwell Junwei Pharmaceutical Tech Co.,Ltd.

Address before: Beijing 100039 Fengtai District, No. 150 West Road

Patentee before: BEIJING TIANCHUAN JUNWEI MEDIC

TR01 Transfer of patent right

Effective date of registration: 20110406

Address after: 102600, Beijing Daxing District bio pharmaceutical industry base, No. 11, wing Rong Street, Sinopharm

Co-patentee after: YICHANG HUMANWELL PHARMACEUTICAL Co.,Ltd.

Patentee after: Beijing Humanwell Junwei Pharmaceutical Tech Co.,Ltd.

Address before: 102600, Beijing Daxing District bio pharmaceutical industry base, No. 11, wing Rong Street, Sinopharm

Patentee before: Beijing Humanwell Junwei Pharmaceutical Tech Co.,Ltd.

TR01 Transfer of patent right

Effective date of registration: 20190107

Address after: 102600 Tianrong Street, Daxing Biomedical Industrial Base, Beijing

Patentee after: Beijing Humanwell Junwei Pharmaceutical Tech Co.,Ltd.

Address before: 102600 Longli National Pharmaceutical Co., Ltd., No. 11 Tianrong Street, Daxing Biomedical Industrial Base, Beijing

Co-patentee before: YICHANG HUMANWELL PHARMACEUTICAL Co.,Ltd.

Patentee before: Beijing Humanwell Junwei Pharmaceutical Tech Co.,Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091216

CF01 Termination of patent right due to non-payment of annual fee